 ERAS-007, a potential best-in-class ERK12 inhibitor, is believed to have broad therapeutic applicability across a wide range of tumor types and indications ERAS-007, a potential best-in-class ERK12 inhibitor, is believed to have broad therapeutic applicability across a wide range of tumor types and indications 